ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 690 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study

    Philip J. Mease1, Désirée van der Heijde2, Robert B.M. Landewé3, Shephard Mpofu4, Proton Rahman5, Hasan Tahir6, Atul Singhal7, Elke Böttcher8, Sandra V. Navarra9, Xuan Zhu10, Aimee Readie10, Luminita Pricop11 and Ken Abrams10, 1Swedish Medical Centre and University of Washington, Seattle, WA, 2Leiden University Medical Centre, Leiden, Netherlands, 3University of Amsterdam, Amsterdam, Netherlands, 4Novartis Pharma AG, Basel, Switzerland, 5Memorial University of Newfoundland and Labrador, St. John's, NF, Canada, 6Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, 7Southwest Rheumatology, Dallas, TX, 8Rheumazentrum Favoriten, Vienna, Austria, 9University of Santo Tomas Hospital, Manila, Philippines, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ

    Background/Purpose: Secukinumab (SEC), a fully human anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms and inhibited radiographic progression versus placebo (PBO) at Week (Wk) 24…
  • Abstract Number: 2584 • 2018 ACR/ARHP Annual Meeting

    Low Incidence of Both New-Onset and Flares of Uveitis in Secukinumab-Treated Patients with Ankylosing Spondylitis: Clinical Trial and Post-Marketing Safety Analysis

    Atul A. Deodhar1, Corinne Miceli-Richard2, Xenofon Baraliakos3, Helena Marzo-Ortega4, Dafna D Gladman5, Ruvie Martin6, Jorge Safi7, Brian Porter7 and Abhijit Shete8, 1Oregon Health & Science University, Portland, OR, 2Rheumatology Department, Paris Descartes University, Paris, France, 3Ruhr-University Bochum, Herne, Germany, 4NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, 5Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, 8Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland

    Background/Purpose: Uveitis, a common extra-articular manifestation of spondyloarthritis (SpA), has an estimated prevalence of 33.2% in patients with ankylosing spondylitis (AS), which increases with duration…
  • Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting

    Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Dongze Wu1, Priscilla Wong1, James F Griffith2, Jiang Yue1 and Lai-Shan Tam3, 1Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 2Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, 3Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
  • Abstract Number: 2608 • 2018 ACR/ARHP Annual Meeting

    Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study

    Iain B. McInnes1, Alan J. Kivitz2, Peter Nash3, Proton Rahman4, Juergen Rech5, Bruce Kirkham6, Sandra V. Navarra7, Kevin Ding8, Emma Ilsley9 and Luminita Pricop10, 1University of Glasgow, Glasgow, United Kingdom, 2Altoona Center for Clinical Research, Duncansville, PA, 3University of Queensland, Brisbane, Australia, 4Memorial University, St John's, NF, Canada, 5University of Erlangen-Nuremberg, Erlangen, Germany, 6Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, 7University of Santo Tomas Hospital, Manila, Philippines, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ

    Background/Purpose: Secukinumab (SEC), a fully human monoclonal IgG1 antibody that selectively neutralizes IL-17A, provided sustained improvement in the signs and symptoms of active psoriatic arthritis…
  • Abstract Number: 990 • 2018 ACR/ARHP Annual Meeting

    Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction

    Mahamudul Haque1, Anil K. Singh1 and Salahuddin Ahmed1,2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: Guanylate binding protein 5 (GBP5), an interferon gamma (IFN-γ) inducible protein, helps to defend against invading pathogens. However, its role and properties beyond anti-viral…
  • Abstract Number: 2697 • 2018 ACR/ARHP Annual Meeting

    Elevated Serum Interleukin-34 Levels Are Correlated with Interstitial Lung Disease in Systemic Sclerosis

    Hiraku Suga1, Ai Kuzumi1, Yoshihide Asano1, Ayumi Yoshizaki1 and Shinichi Sato2, 1Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2The University of Tokyo, Department of Dermatology, Tokyo, Japan

    Background/Purpose: Interleukin (IL)-34 is a hematopoietic cytokine, which promotes survival, proliferation, and differentiation of monocytes and macrophages. We investigated serum IL-34 levels in patients with…
  • Abstract Number: 991 • 2018 ACR/ARHP Annual Meeting

    Critical Role of Interleukin-1α (IL-1α) in IL-1β-Induced Inflammatory Responses: Cooperation with NF-κBp65 in Transcriptional Regulation

    Anil K. Singh1, Sabrina Fechtner1, Mukesh Chourasia2, Jerry Sicalo1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India

    Background/Purpose: Interleukin-1β (IL-1β) and IL-1α are cytokines of IL-1 family that orchestrate acute and chronic inflammatory diseases. However, their distinct role or the extent of…
  • Abstract Number: 2801 • 2018 ACR/ARHP Annual Meeting

    A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis

    Kazuhiko Higashioka1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiuchi3 and Hiroaki Niro4, 1Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    Background/Purpose: A plethora of evidence from genome-wide association studies and relevant animal models implicates a pivotal role of T cells in the pathogenesis of rheumatoid…
  • Abstract Number: 1659 • 2018 ACR/ARHP Annual Meeting

    Sustained Improvements in Physical Function, Quality of Life, and Work Productivity after Ixekizumab Therapy in Patients with Active Psoriatic Arthritis: 3-Year Results

    Roy Fleischmann1, Vinod Chandran2, Eric Lespessailles3, Julie Birt4, Olivier Benichou4, Janelle Erickson4 and Catherine Shuler4, 1University of Texas Southwestern Medical Center, Dallas, TX, 2Krembil Research Institute and University of Toronto, Toronto, ON, Canada, 3University of Orléans, Orléans, France, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements compared to placebo not only in disease activity but also in various…
  • Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting

    Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis

    Sandeep Kansurkar1, Ankita Singh2, Ramnath Misra3 and Amita Aggarwal3, 1Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…
  • Abstract Number: 2022 • 2018 ACR/ARHP Annual Meeting

    Evidence of Inflammation Amplification By Interleukin-6 and Interleukin-17A in Synovial Compartment of Juvenile Idiopathic Arthritis – Enthesitis Related Arthritis

    Rutviz Mistry1, Sandeep Kumar1, Sanjukta Majumder2, Sandeep Kansurkar3, Amita Aggarwal1 and Ramnath Misra1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: F759 mice with single amino-acid substitution in IL-6 receptor gp130 (Y759F) develops features of autoimmune disorders like arthritis, multiple sclerosis due to IL-17A and IL-6…
  • Abstract Number: 2411 • 2018 ACR/ARHP Annual Meeting

    The Ovarian Reserve Measuring the Anti-Müllerian Hormone Is Not Diminished in Patients with Rheumatoid Arthritis Compared to the Healthy Population

    Mireia López-Corbeto1, Sara Marsal1, Andrea Pluma2, Sergio Martinez2, Maria Lopez-Lasanta2, Agusti Sellas-Fernandez2, Juan José de Agustín2 and Mireia Barcelo2, 1Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 2Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Rheumatoid Arthritis (RA) is the most prevalent chronic inflammatory arthritis, affecting 0.5-1% worldwide population and predominates in females. Altered fertility has been reported due…
  • Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting

    Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial

    Helena Marzo-Ortega1, Joachim Sieper2, Alan J. Kivitz3, Ricardo Blanco4, Martin Cohen5, Evie Maria Delicha6, Susanne Rohrer6 and Hanno Richards6, 1NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, 2University Clinic Benjamin Franklin, Berlin, Germany, 3Altoona Center for Clinical Research, Duncansville, PA, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5McGill University, Montreal, QC, Canada, 6Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
  • Abstract Number: 2559 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: Two-Year Follow-up from a Phase 3 Study

    Ana-Maria Orbai1, Amanda M. Gellett2, Lisa Kerr2 and Arnaud Constantin3, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Eli Lilly and Company, Indianapolis, IN, 3Hopital Pierre-Paul Riquet, Toulouse, France

    Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets IL-17A, was superior to placebo (PBO) at Week (Wk) 24 for treating PsA signs and…
  • Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting

    Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis

    Ana-Maria Orbai1, Dafna D Gladman2, Julie Birt3, Amanda M. Gellett3, Chen-Yen Lin3 and Tore Kvien4, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Toronto, Toronto, ON, Canada, 3Eli Lilly and Company, Indianapolis, IN, 4Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology